Expanding the Menu of HIV Prevention Options

A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

Deanna Kerrigan, Andrea Mantsios, R. Grant, M. Markowitz, P. Defechereux, M. la Mar, Sarah Beckham, P. Hammond, D. Margolis, M. Murray

Research output: Contribution to journalArticle

Abstract

Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAIDS and Behavior
DOIs
StateAccepted/In press - Dec 30 2017

Fingerprint

HIV
Injections
Interviews
San Francisco
Decision Making
cellulose acetate-butyrate
Guidelines
Research

Keywords

  • HIV
  • Long-acting injectable
  • Men
  • PrEP
  • Providers
  • Qualitative
  • Risk behavior

ASJC Scopus subject areas

  • Social Psychology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Expanding the Menu of HIV Prevention Options : A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. / Kerrigan, Deanna; Mantsios, Andrea; Grant, R.; Markowitz, M.; Defechereux, P.; la Mar, M.; Beckham, Sarah; Hammond, P.; Margolis, D.; Murray, M.

In: AIDS and Behavior, 30.12.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{fe6e217fb4974d009a78b8c9f65354ba,
title = "Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States",
abstract = "Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study ({\'E}CLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.",
keywords = "HIV, Long-acting injectable, Men, PrEP, Providers, Qualitative, Risk behavior",
author = "Deanna Kerrigan and Andrea Mantsios and R. Grant and M. Markowitz and P. Defechereux and {la Mar}, M. and Sarah Beckham and P. Hammond and D. Margolis and M. Murray",
year = "2017",
month = "12",
day = "30",
doi = "10.1007/s10461-017-2017-x",
language = "English (US)",
pages = "1--10",
journal = "AIDS and Behavior",
issn = "1090-7165",
publisher = "Springer New York",

}

TY - JOUR

T1 - Expanding the Menu of HIV Prevention Options

T2 - A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

AU - Kerrigan, Deanna

AU - Mantsios, Andrea

AU - Grant, R.

AU - Markowitz, M.

AU - Defechereux, P.

AU - la Mar, M.

AU - Beckham, Sarah

AU - Hammond, P.

AU - Margolis, D.

AU - Murray, M.

PY - 2017/12/30

Y1 - 2017/12/30

N2 - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

AB - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

KW - HIV

KW - Long-acting injectable

KW - Men

KW - PrEP

KW - Providers

KW - Qualitative

KW - Risk behavior

UR - http://www.scopus.com/inward/record.url?scp=85039736006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039736006&partnerID=8YFLogxK

U2 - 10.1007/s10461-017-2017-x

DO - 10.1007/s10461-017-2017-x

M3 - Article

SP - 1

EP - 10

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

ER -